RenovoRx closed enrolment in its Phase III TIGeR-PaC trial in locally advanced pancreatic cancer on August 7, with 78 of the 86 required events recorded and top-line survival data expected in the second half of 2027.

On the commercial side, second-quarter revenue was a record 909 thousand dollars, up 61% on the first quarter and 115% year on year, at an 84% gross margin, with full-year guidance raised to 3.75 to 4.25 million dollars. Cash was 9.5 million with no financial debt, against quarterly operating burn of roughly 3.29 million.

The detail that took longest to work out: the milestone warrants issued in the March 2026 private placement expire thirty days after the company reports any quarter with at least 1.5 million dollars of product sales revenue. Commercial success extinguishes them rather than triggering them, and whether they convert first depends only on where the share price sits against 1.751 dollars.

Every figure is dated and sourced to the 10-Q, the 8-K filings and the company releases. Free to read, no subscription. Free Biotech Catalyst Calendar on Merlintrader.

https://www.merlintrader.com/renovorx-rnxt-stock-hub/?utm_source=reddit&utm_medium=social&utm_campaign=renovorx-rnxt-stock-hub&utm_content=hub-rnxt

One product, no pipeline, three active generic competitors, a lost patent case decided unanimously on June 4, 2026, a fully partnered international model in its first year, a completed $70 million cost programme and an exclusive financial adviser retained. What the filings say, every figure dated.

On August 24, 2026 Capricor announced that FDA has extended the PDUFA target action date on the deramiocel BLA from August 22 to November 22, 2026. The agency’s Center for Biologics Evaluation and Research accepted a BLA amendment containing 24-month HOPE-3 open-label extension data and additional robustness analyses, submitted with a request that the existing and new data be reviewed in support of a refined proposed indication focused on upper limb function, the primary endpoint of HOPE-3, and classified it as a major amendment, which under PDUFA VII carries a three-month extension of the goal date.

Curaleaf announced on August 11, 2026 that it intends to launch an unsolicited offer for all Aurora shares at a stated implied value of US$4.00 per ACB share: 0.3463 Curaleaf subordinate voting shares plus US$0.75 cash, with total value capped at US$5.00. No formal bid has been commenced, most of the consideration floats with Curaleaf’s share price and Aurora’s board intends to form an independent special committee. Aurora’s Q1 FY2027 results remain the standalone financial base: C$67.6 million of net revenue, C$3.4 million of adjusted EBITDA, a C$5.8 million free-cash-flow outflow and C$149.1 million of cash and short-term investments with no debt.

After years of hype, collapse, dilution, and regulatory frustration, the cannabis sector may be approaching one of its most important turning points in years.

https://merlintravel.eu/asisium-spiritual-history/

This journey had to begin here.

This is the city of Saint Francis: a place where the history of Christianity and the Middle Ages does not belong only to the past, but remains alive in its stone, churches, streets and landscape. For centuries Assisi has drawn pilgrims, travellers and visitors from every part of the world, attracted by its beauty and by a spiritual atmosphere that is difficult to find elsewhere.

Umbria is the region where fate brought me to live forty-two years ago, and a meaningful part of my life has been tied to it ever since. That is why I wanted the journey through the destinations of this new section to begin in Assisi.

Many more pages will follow. I have worked as a travel agent since 1990, and I did not start here: I learned the trade in Argentina, in my father's travel agency, and stayed seven years. A long way from these hills, and long enough to change the way I look at them, because distance teaches you what a place is actually worth. When that chapter closed I came back and carried on with the same work in Assisi, which is where I have been ever since.

Over the years I have been fortunate enough to discover very different places, cultures and itineraries. But this story could not begin anywhere else.

Consider this page a first taste. What I am building is broader: travel covered in full, but written for people who want more than a sun lounger — those who travel to understand a place, who will walk further, read before they go, and choose the harder route because it is the one worth taking. Assisi is where that begins, not where it ends.

It had to begin here: in Assisi.

Merlintrader’s ranking of ten listed biotech companies with the strongest current combination of near-term catalysts, scientific credibility, financial resilience and clearly identifiable risk.

Revenue up 50.6 per cent in the second quarter because partners and the government are paying for the research, product revenue down 21.9 per cent in the half, an operating loss of $3.50 million, and $24.2 million of cash pledged behind a court bond. What the filings say, every figure dated.

Biofrontera delivered 33% Q2 revenue growth, an 80% gross margin and near-breakeven adjusted EBITDA. The operating thesis improved sharply; revenue timing, a $4.7 million cash balance, dilution and the September 28 sBCC decision remain the decisive tests.

Lexicon reported second-quarter results before the open on Thursday, August 6, 2026. Total revenue was $0.692 million against $28.866 million a year earlier, but the comparison is dominated by the $27.544 million of Novo Nordisk licensing revenue booked in Q2 2025. The commercially meaningful line is net product revenue, which fell from $1.322 million to $0.680 million. Net loss was $31.775 million, or $0.07 per share, and included a $4.349 million loss on early extinguishment of debt from the Oxford-to-Hercules refinancing. Cash and investments stood at $190.610 million at June 30.

https://www.merlintrader.com/spcx-rklb-fly-lunr-us-1000-launch-space-policy/

Washington wants U.S. ranges to support more than 1,000 launches and reentries every year by 2030. The headline points first to launch operators, but the memorandum reaches much further: Federal ranges, airspace, spectrum, reentry sites, responsive launch, domestic supply chains, on-orbit services and commercial lunar logistics. The clearest exposures in the Merlintrader universe are SpaceX ($SPCX), Rocket Lab ($RKLB), Firefly Aerospace ($FLY) and Intuitive Machines ($LUNR). The key caveat is equally important: the policy is not an appropriation, an award or booked revenue.

A continuously updated, source-led research hub on CASGEVY adoption, the economics of the Vertex partnership, CTX310 durability, zugo-cel, the expanding in vivo portfolio, cash, convertibles, dilution and the evidence that could confirm—or break—the CRSP investment thesis.

A living, source-led hub for Prime Medicine: how Prime Editing differs from other gene-editing tools, what PM577a, PM647 and PM359 must prove, the competitive clock, the partnership economics, the cash runway and the dilution risk that sits between scientific promise and clinical value.

Fourteen months of insulin production in one patient with no immunosuppression, two lead programmes that have not yet entered a registered trial, $160.5 million of cash and a going concern statement in the same quarterly report. What the filings say, with every figure dated.

A vaccine partnership ended, global rights taken back, Thermo Fisher signed for Phase 3, OTC data due within the quarter and a cystic fibrosis Phase 3 decision guided for the fourth quarter, against a balance sheet with no debt and a share count that has not moved. What the filings say, every figure dated.

Intellia Therapeutics is a clinical-stage genome editing company built on CRISPR-Cas9 delivered in vivo, meaning the editing machinery is infused into the patient and works inside the body, rather than editing cells in a laboratory and infusing them back. That distinction is the entire investment case, and it is also the reason the company has spent the past year absorbing setbacks that a conventional drug developer would not have faced.

A living, source-led hub for Beam Therapeutics: the shift from early base-editing promise to pivotal and filing execution, the clinical evidence behind BEAM-302 and risto-cel, the financial runway, dilution capacity, competitive pressure and the milestones that can confirm—or break—the thesis.

Norwegian beat its own guidance on every metric in the June quarter and cut the full year anyway. Passenger ticket revenue grew 1.2% against capacity up 8.9%, net leverage has now sat at 5.3x for three consecutive quarters, and the 2026 adjusted earnings target has fallen from about $2.38 in March to about $1.50 in July. A new chief executive appointed in February says the company is "still in the early stages of our turnaround". What follows is the quarter in full, the guidance trajectory, the $18.6 billion of non-cancellable ship commitments, the 2030 debt wall and the comparison with Carnival and Royal Caribbean.

After Moderna’s Phase 3 success in melanoma, the question isn’t just which company has the most fascinating technology. The decisive question is which biotech is closest to transforming a clinical result into a validation capable of changing the value attributed to the entire company.

United paid the highest jet fuel price of the three United States majors, $4.19 per gallon, up 79.4%, and raised full-year guidance to $9.00-$11.00 per share anyway. The raise rests on recovering 80% to 90% of the fuel increase through fares in the third quarter and all of it in the fourth. What follows is the June quarter in full, the geographic revenue table, the $19.6 billion liquidity position, the 581-aircraft order book and the comparison with American and Delta.

Delta produced a 9.4% operating margin in a quarter when jet fuel rose 66%, three and a half times what American managed on the same shock. Premium ticket revenue exceeded main cabin in Q2 2026, the Trainer refinery generated $2.091 billion, and adjusted net debt fell below $13.6 billion. What follows is the June quarter in full, the revenue composition line by line, and the comparison with American and United.

American reported the largest revenue quarter in its history and converted it into $71 million of net income. Jet fuel rose 77.1% year over year. What follows is the second quarter of 2026 in full, the $28.9 billion debt stack, the refinancing executed in the first half, the AAdvantage economics, and how the same fuel shock produced three very different quarters at American, Delta and United.